Clearside Biomedical, Inc. to Participate in 2017 JMP Securities Life Sciences Conference

ALPHARETTA, Ga., June 13, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will participate in an Ophthalmology panel discussion at the 2017 JMP Securities Life Sciences Conference on Tuesday, June 20, 2017 at 4:00 p.m. ET at St. Regis Hotel in New York, NY.  There will be no formal presentation and the event will not be webcast.

About Clearside

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness.  Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, RVO, diabetic macular edema and wet age-related macular degeneration. CLS-TA for suprachoroidal administration, used either alone or together with an intravitreal anti-VEGF agent, is part of Clearside’s pipeline for the treatments of unmet or underserved blinding eye diseases where the pathologies manifest in the choroid and retina. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.

Contacts:

Stephen Kilmer
Investor Relations
(678) 270-3631
[email protected]

Charles Deignan
Chief Financial Officer
(678) 270-4005
[email protected]